ELUTIA INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
ELUT$0.93+11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In Thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine Months Ended | ||||||
| · · September 30, | ||||||
| · · 2026 · · 2025 | ||||||
| Net loss | | $(16,400) | $(17,411) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | |||
| Depreciation and amortization | | 1,082 | 2,488 | |||
| Gain on sale of Orthobiologics Business | | (425) | — | |||
| Gain on sale of SimpliDerm Business, excluding divestiture costs | | | (5,617) | | | — |
| (Gain) loss on revaluation of warrant and derivative liabilities | | 768 | (12,518) | |||
| Amortization of deferred financing costs and debt discount | | 135 | 161 | |||
| Interest expense recorded as additional revenue interest obligation and long-term debt | | 398 | 3,892 | |||
| Stock-based compensation | | 2,696 | 4,342 | |||
| Changes in right-of-use assets and lease liabilities and lease incentives received | | | 459 | | | — |
| Payments on revenue interest obligation | | | (3,300) | | | — |
| Changes in operating assets and liabilities: | | | | | ||
| Accounts receivable | | 268 | (1,277) | |||
| Inventory | | 381 | (1,093) | |||
| Insurance receivables of litigation costs | | | 2,321 | | | 199 |
| Prepaid expenses and other | | 1,462 | 1,898 | |||
| Accounts payable and accrued expenses | | (2,302) | 3,308 | |||
| Contingent liability for legal proceedings | | | (7,777) | | | (4,049) |
| Other liabilities | | 1,431 | 64 | |||
| Net cash used in operating activities | | (24,420) | (19,996) | |||
| INVESTING ACTIVITIES: | | | | |||
| Proceeds from sale of Orthobiologics Business | | | 425 | | | — |
| Proceeds from sale of SimpliDerm Business | | | 7,700 | | | — |
| Expenditures for property and equipment | | (592) | (1,022) | |||
| Net cash provided by (used in) investing activities | | 7,533 | (1,022) | |||
| FINANCING ACTIVITIES: | | | | |||
| Proceeds from registered direct offering and warrants, net of offering costs | | | — | | | 13,796 |
| Proceeds from long-term debt and warrants | | 10,000 | — | |||
| Debt issuance costs | | | (337) | | | — |
| Repayments of insurance premium financings | | | — | | | (1,101) |
| Payments for taxes upon vesting of restricted stock units | | | (111) | | | (307) |
| Proceeds from stock option exercises and issuance of common stock under ESPP | | 78 | 112 | |||
| Net cash provided by financing activities | | 9,630 | 12,500 | |||
| | | | | | | |
| Net decrease in cash and cash equivalents | | (7,257) | (8,518) | |||
| | | | | | | |
| Cash and cash equivalents, beginning of period | | 36,350 | 13,239 | |||
| Cash and cash equivalents, end of period | | $29,093 | $4,721 | |||
| | | | | | | |
| Supplemental Cash Flow and Non-Cash Financing Activities Disclosures: | | | | |||
| Cash paid for interest | | $3,481 | $560 | |||
| Issuance of common stock as payment under revenue interest obligation | | $— | | $2,200 | ||
| Operating lease right-of-use assets executed | | $113 | | $2,271 | ||
| Conversion of Common Warrants and Prefunded Warrants to common stock | | $1,390 | | $727 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.